Impact of generic entry to off-patent branded medicines in Japanese pharmaceutical market

Abstract

The Japanese pharmaceutical market is known for having a relatively low market penetration of generic medicines. However, the velocity of generic penetration varies among medicines. Looking at current sales and share of off-patent branded medicines and generic medicines in Japanese pharmaceutical market, our main aim is to identify the factors associated with sales reductions of off-patent medicines and price competition caused by generic entry in the Japanese pharmaceutical market. We showed as one result that an increase in the number of generic maker entries significantly increases both price competition and sales reductions of off-patent branded medicines. As a second factor of note, we found that being subject to “NHI Drug Price Premium for Promoting the Creation of New Drugs and the Elimination of Off-label Use” before generic entry is related to maintaining sales of off-patent branded medicines after generic entry. The importance of generic medicines is increasing in association with the hypertrophy of health care expenditures in Japan. Efficient polices and corporate strategies reflecting market principles are strongly needed. Detailed results of this study on what determines whether sales and prices of off-patent medicines significantly decrease after generic entry in the Japanese pharmaceutical market should be useful for this purpose.

Keywords

Generic entry sales reduction price divergence rate Z2 price reduction authorized generic medicine Japan

Get full access to this article

View all access options for this article.

References

Organization for Economic Co-operation and Development. Health data 2016.

Garattini

Tediosi

. A comparative analysis of generic markets in five European counties. Health Policy 2000; 51: 149–162.

Iizuka

. Generic entry in a regulated pharmaceutical market. Japan Econom Rev 2009; 60: 63–81.

QuintilesIMS. IMS-Base JPM. 2009–2015.

Atanu

Henry

Howard

et al.

Generic competition in the US pharmaceutical industry. Int J Econom Business 2006; 13: 15–38.

Ivan

Jaume

Joan-Ramon

. Generic entry into the regulated spanish pharmaceutical market. Rev Indus Organiz 2009; 34: 373–388.

Takizawa

Urushihara

Tanaka

et al.

Price difference as a predictor of the selection between brand name and generic stains in Japan. Health Policy 2015; 119: 612–619.

Joel

. The effect of generic competition on the price of brand-name drugs. Health Policy 2004; 68: 47–54.

Simoens

. A review of generic medicine pricing in Europe. Generics Biosimilar Initiative J 2011; 1: 8–12.

10.

Dylst

Simoens

. Does the market share of generic medicines influence the price level? Pharmacoeconomics 2011; 29: 875–882.

11.

Caves

Whinston

Hurwiz

. Patent expiration, entry, and competition in the US pharmaceutical industry. Brookings Papers on Economic Activities, Microeconomics 1991; 1980: 1–48.

12.

Conti R and Berndt E. Specialty drug prices and utilization after loss of U.S. Patent exclusivity, 2001–2007. NBER Working Paper No.20016. 2014.

13.

Iizuka

Kubo

. The generic drug market in Japan: will it finally take off? Health Econom Policy Law 2011; 6: 369–389.

14.

Riku

. Current situation for generic drugs in Japan. J Generic Med 2005; 2: 219–231.

15.

Grabowski H, Long G and Mortimer R. Recent trends in brand-name and generic drug competition. J Med Econom 2014; 17: 207–214.

16.

Hudson

. Generic take-up in the pharmaceutical market following patent expiry: a multi-country study. Int Rev Law Econom 2000; 20: 205–221.

17.

Japanese Central Social Insurance Medical Council. NHI price listing. http://www.mhlw.go.jp/stf/shingi/shingi-chuo.html?tid=128154 (in Japanese) (accessed 16 September 2008).

18.

World Health Organization Collaborating Center for Drug Statistic Methodology; Anatomical Therapeutic Chemical (ATC) Classification System, https://www.whocc.no/atc_ddd_index_and_guidelines/atc_ddd_index/.

19.

Shibata

Uemura

Suzuki

. Factors that affect the acquisition of reward premiums for promotion of innovative drug discovery in Japan. Therapeut Innovat Regul Sci 2016; 50: 56–65.

20.

Shibata

Uemura

Suzuki

. Impact of premium rewards for the promotion of innovative drug discovery on the Japanese pharmaceutical market: an analysis by therapeutic area. Therapeut Innovat Regul Sci 2016; 50: 49–55.

21.

Wakutsu

Nakamura

. Analyzing the benefits from new NHI drug pricing system in Japan: factor decomposition and simulation. Iryo to Syakai 2015; 25: 205–220.

22.

Takayama

Narukawa

. Investigation of factors affecting the degree of price gap between the national health insurance reimbursement price and the actual market price of new drugs. Regulat Sci Med Product 2016; 6: 295–305.